Result card

  • ECO2: What quantity of resources is used when delivering uPA/PAI-1 (Femtelle), OncotypeDx™ or MammaPrint® and what quantity of resources are used when delivering standard clinical practice?
English

What quantity of resources is used when delivering uPA/PAI-1 (Femtelle), OncotypeDx™ or MammaPrint® and what quantity of resources are used when delivering standard clinical practice?

Authors: Isaura Vieira, Mirella Corio, Maria Rosaria Perrini, Matteo Ruggeri

Internal reviewers: Hanan Bell, Marco Oradei, Michelle O'Neill, Patricia Harrington, Kristi Liiv

Selected studies extracted from the basic literature search were analysed. Eight studies {1; 2; 3; 4; 5; 7; 8; 9} were found to be relevant to this question.

The quantity of resources used, excluding the resources associated with the delivery of the prognostic tests, will be highly dependent on the distribution of patients over the risk profiles and on the distribution of the duration in each of the different health states. Thus the amount of resources used, after the risk of recurrence profile distribution (using the prognostic tests or standard of care), will need to be modelled separately for each of the treatment scenarios and patient health states.

A number of the studies selected and analysed describe the quantity of resources used in their models {2; 3; 4; 5}. These estimates of resource utilisation were based on different sources of information including treatment guidelines, observational studies, and retrospective studies leading to different estimates of overall resource utilisation in different studies.

This variability, based on the inconsistency of the data, could be reduced with further high quality evidence from randomised controlled trials (RCTs) as discussed in the EFF domain.

Due to the limitations referred to in the domain introduction, the objective here is to prepare a rough description of the structure of an economic evaluation. It was not considered appropriate to present the unit costs for each resource identified.

Critical
Partially
Vieira I et al. Result Card ECO2 In: Vieira I et al. Costs and economic evaluation In: Jefferson T, Vicari N, Raatz H [eds.]. Prognostic tests for breast cancer recurrence (uPA/PAI-1 [FEMTELLE], MammaPrint, Oncotype DX ) [Core HTA], Agenzia nationale per i servizi sanitari regionali (age.na.s), Italy ; 2013. [cited 7 February 2023]. Available from: http://corehta.info/ViewCover.aspx?id=113

References